The mutagenic processes result from loss of integral HR pathway components; therefore, cancers with non-BRCA HR defects, such as germline or somatic mutations in PALB2, RAD51B, RAD51C, or RAD51D, or their inactivation through promoter methylation [3], would also receive a positive treatment prediction. This evidence concerns the gene RAD51C and cancer.